tbuckley/cabot-search huggingface dataset:
Effect of Regular Exercise Commenced in Early Pregnancy on the Incidence of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Randomized Controlled Trial
Authors: Chen Wang, Yumei Wei, Xiaoming Zhang, Yue Zhang, Qianqian Xu, Shiping Su, Li Zhang, Chunhong Liu, Yaru Feng, Chong Shou, Kym J. Guelfi, John P. Newnham, Huixia Yang
Journal: Diabetes Care (2016)

Gestational diabetes mellitus (GDM) is a common complication in pregnancy that is associated with a higher risk of adverse health outcomes for mothers and offspring, not only during the perinatal phase but also in the long term, well into future generations. Exercise has been confirmed as effective in delaying the progression of glucose intolerance in type 2 diabetes. However, whether exercise is effective for the prevention of GDM is not clear because the few randomized controlled trials (RCTs) investigating this issue show conflicting results (1). Therefore, we conducted an RCT (NCT02304718) to evaluate whether regular cycling commenced in early pregnancy could reduce the incidence of GDM in Chinese pregnant women.

A total of 300 singleton pregnant women with a mean prepregnancy BMI of 26.78 ± 2.75 kg/m2 before 12+6 gestational weeks were recruited and randomly allocated into either an exercise intervention group (EG) or a control group (CG) in a 1:1 ratio. Participants allocated to the CG …
Ineffective Erythropoiesis in β-Thalassemia Is Characterized by Enhanced Survival Mechanisms That Reduce P21-Mediated Cell Death.
Authors: Ilaria Libani, Raffaella Schiro, Thomas Scholzen, Pedro Ramos, Ella Guy, Margrit Kernbach, Bettina Baron-Luehr, Laura Breda, Matteo Porotto, Maria Domenica Cappellini, Patricia Giardina, Johannes Gerdes, Stefano Rivella
Journal: Blood (2006)
Impaired Anti-HBV Vaccine Response in Non-Cirrhotic Chronic HCV Patients is not Overcome by Double dose Regimen: A Randomized Control Trial
Authors: M.G. Pessoa, R. Porto, D. Mazo, C.P. Oliveira, N. Terrault, J. Dodge, P.M. Zitelli, J.R. Pinho, M. Lopes, F.J. Carrilho
Journal: Journal of Hepatology (2016)
Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML)
Authors: Jihane C Khalife, Hanna S Radomska, Jennifer Saultz, Ramasamy Santhanam, Xiaomeng Huang, Hongyan Wang, John P. Curfman, Yue-Zhong Wu, Pia Hoellerbauer, Houda Alachkar, Adrienne M Dorrance, Michael A. Caligiuri, Ramiro Garzon, Jason H. Mendler, Guido Marcucci
Journal: Blood (2013)
Pre-Transplant Expressions of Micrornas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT)
Authors: Mohamed L. Sorror, Theodore A Gooley, Kirsteen Maclean, Shamali Roy, Jesse Hubbard, Mario Marcondes, Beverly Torok-Storb, Tewari Muneesh
Journal: Blood (2015)
The treatment of metastatic rectal cancer (MRC): A review of the multidisciplinary approach at The Ottawa Hospital Cancer Centre (TOHCC).
Authors: T. Di Valentin, T. R. Asmis, R. A. Auer
Journal: Journal of Clinical Oncology (2010)

e14132 Background: There is significant controversy surrounding the management of surgically resectable MRC. The use and timing of neoadjuvant chemotherapy, pelvic radiation, and relative risks and benefits of a combined surgical resection are areas of debate among surgeons, medical, and radiation oncologists. The TOHCC multidisciplinary Cancer Conferences (MCC) provide an opportunity to discuss these cases and propose treatment plans for these patients. Methods: We conducted a retrospective chart review of all the cases of MRC which were discussed at MCC at the TOHCC from November 2007 until October 2009. Information collected included patient demographics, site of metastases, the treatment they received prior to their case being discussed at MCC (past surgeries, chemotherapy, radiotherapy), the treatment plan discussed at MCC, treatment actually administered post MCC discussion, and patient outcome at 6 months. Results: Forty-two patients with MRC were reviewed. The most common sites of metastases were liver (45.2%) and lung (31%). Once diagnosed with metastatic disease, prior to the MCC, patients had received the following treatments alone or in combination: chemotherapy (33.3%), radiotherapy (21.4%), surgery (19.0%), no treatment (n = 57.1%). After the MCC, 38 patients (90.5%) received the treatment recommended during the review, while 4 (9.5%) did not. Treatment post MCC included: chemotherapy (neoadjuvant: 38.1%; adjuvant: 23.8%; palliative: 28.6%), radiotherapy (neoadjuvant: 14.3%; adjuvant: 7.1%; palliative: 7.1%) and surgery (31.0%). Conclusions: There is no standardized approach to the management of MRC. Given its complexity, many cases are reviewed at MCC, which allow coordination for multidisciplinary care of these patients. The results of this study suggest that in a majority of cases, the recommendations brought forth are acted upon. Given that these meetings have a significant impact on the treatment plan and outcome of patients with MRC, they should represent the standard of care when treating this disease. No significant financial relationships to disclose.
Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand
Authors: Nonglak Kanitsap, Naree Wannissorn, Arnuparp Lekhakula, Jakrawadee Julamanee, Archrob Khuhapinant, Chittima Sirijerachai, Kanchana Chansung, Lalita Norasetthada, Weerasak Nawarawong, Suporn Chuncharunee, Pimjai Niparuck, Kitsada Wudhikarn, Udomsak Bunworasate, Tontanai Numbenjapon, Kannadit Prayongratana, Somchai Wongkhantee, Peerapon Wong, Tawatchai Suwanban, Nisa Makruasi, Tanin Intragumtornchai
Journal: Blood (2015)
Prognostic Impact Of a Newly Defined Structurally Complex Karyotype In Patients With AML and MDS After Allogeneic Stem Cell Transplantation
Authors: Christiane E Dobbelstein, Elke Dammann, Eva M Weissinger, Michael Stadler, Matthias Eder, Brigitte Schlegelberger, Arnold Ganser, Gudrun Gohring
Journal: Blood (2013)
P1.32: Primary Lung Cancer Presenting as Pneumothorax
Authors: Fadil Gradica, Flora Gradica, Valbona Rexha, Lutfi Lisha, Sali Gradica, Dhimitraq Argjiri, Alma Cani, Donika Lala, Alketa Pere, Elez Selimi
Journal: Journal of Thoracic Oncology (2016)
Increasing Incidence of Cancer in Persons Living with HIV Coinfected with HCV: An Additional Impact of HCV Infection?
Authors: A. Mena, H. Meijide, I. Rodríguez-Osorio, Á. Castro-Iglesias, S. Pértega, G. Rodríguez-Martínez, B. Pernas, J. Baliñas, J.D. Pedreira, E. Poveda
Journal: Journal of Hepatology (2016)
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease
Authors: A. Lopategi, B. Rius, L.-V. Cristina, J. Alcaraz-Quiles, V. García-Alonso, E. Titos, V. Arroyo, J. Clària
Journal: Journal of Hepatology (2016)
Genetic and epigenetic analysis of schizophrenia in blood—a no-brainer?
Authors: Andrew E. Jaffe, Joel E. Kleinman
Journal: Genome Medicine (2016)

Several recent studies have investigated either genetic or epigenetic variation in schizophrenia. A recent study presents comprehensive analyses of blood samples to better characterize the combined role of genetic and epigenetic variation in schizophrenia. While the paper identifies significant associations with schizophrenia risk and diagnosis, the potential relevance to the brain in schizophrenia is questionable.
Secretory Leukocyte Protease Inhibitor Drives Hepatic Resolution Responses in Acute Liver Failure through Modulation of the Mer Tyrosine Kinase Pathway
Authors: E. Triantafyllou, A. Wilhelm, L. Possamai, O. Pop, E. Liaskou, C. Bernsmeier, W. Khamri, G. Petts, S. Davies, R. Abeles, Z. Stamataki, K. Woollard, Y. Ma, A. Quaglia, J. Wendon, M. Thursz, D. Adams, S. Curbishley, C. Weston, C. Antoniades
Journal: Journal of Hepatology (2016)
P1194 : Delayed bile acid uptake with metabolic consequences in NA+-taurocholate cotransporting polypeptide knockout mice
Authors: D. Slijepcevic, J.M. Donkers, C. Kaufman, C.G.K. Wichers, E.H. Gilglioni, F.A. Lempp, S. Duijst, D.R. de Waart, R.P.J. Oude Elferink, W. Mier, B. Stieger, U. Beuers, S. Urban, S.F.J. van de Graaf
Journal: Journal of Hepatology (2015)
Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML
Authors: Juliana Vélez Luján, Niki Zacharias, Dinesh Rakheja, Tushar D Bhagat, Jaehyuk Lee, Prasanta Dutta, Doriann Gonzalez, Michael Andreeff, Pratip K Bhattacharya, Amit Verma, Marina Konopleva
Journal: Blood (2015)
Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution.
Authors: Hae Jin Park, Kyubo Kim, Eui Kyu Chie, Jin-Young Jang, Sun Whe Kim, Do-Youn Oh, Yung-Jue Bang
Journal: Journal of Clinical Oncology (2016)

370 Background: The patterns of failure after resection for duodenal cancer are very limited, and the benefit of adjuvant chemoradiotherapy has not been proven. We compared the treatment outcomes of surgery alone to those of surgery followed by adjuvant chemoradiotherapy (CRT) for duodenal cancer. Methods: Forty-seven patients with duodenal cancer underwent pancreaticoduodenectomy between January 1991 and February 2013. There were 33 males and 14 females, and their median age was 62 years (range, 31-80). Twenty-two patients (47%) received adjuvant CRT, and 25 (53%) did not. Postoperative radiotherapy was delivered to tumor bed and regional lymphatics (dose range = 40-55.4 Gy). All the patients underwent CRT concurrently with 5-fluorouracil. Median follow-up period was 31 months (range, 6-286). Results: Nodal stage and stage group were more advanced in CRT(+) group (p = 0.003 and 0.002, respectively). Locoregional recurrence (LRR) occurred in 11 patients; 8 out of 25 in CRT(-) and 3 out of 22 in CRT(+) group. Distant metastasis (DM) occurred in 19 patients; 7 out of 25 in CRT(-) and 12 out of 22 in CRT(+) group. Five patients experienced LRR and DM, and 3 of them were synchronous. Five-year overall survival rates of CRT(-) and CRT (+) group were 50% and 47%, respectively (p = 0.794). Five-year locoregional relapse-free survival rates of CRT(-) and CRT(+) group were 68% and 80%, respectively (p = 0.267). On multivariate analysis, the addition of CRT after curative resection was the only prognostic factor predicting superior locoregional relapse-free survival (p = 0.049). No patient suffered from grade 3 or higher toxicity during or after CRT. Conclusions: The addition of CRT after pancreaticoduodenectomy was associated with improvement of local control in duodenal cancer. Given the high LRR in surgery alone group, adjuvant CRT should be considered.
Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT
Authors: Michel Van Gelder, Liesbeth de Wreede, Anja Henseler, Anja van Biezen, Dietger Niederwieser, Michal Karas, Niels S. Andersen, Martin Gramatzki, Peter Dreger, Donald W. Bunjes, Eefke J Petersen, Michael N Potter, Dietrich Beelen, Ibrahim Yakoub-Agha, Jan J Cornelissen, Nigel Russell, Jurgen Finke, Helene Schoemans, Didier Blaise, Paneesha Shankara, Antonin Vitek, Martin Bornhäuser, Stefan Schönland, Nicolaus Kröger, Johannes Schetelig
Journal: Blood (2014)
Comparison of Antiviral Efficacy between Tenofovir Monotherapy and Tenofovir-Based Combination Therapy in Chronic Hepatitis B with Resistance to Antiviral Agents: A Interim Result of Multicenter Cohort Study
Authors: K.S. Chung, B.K. Kim, K.T. Yoon, H. Park, C.W. Kim, Y.S. Kim, J.Il Lee, S. Up Kim, D.Y. Kim, S.G. Kim, Y.-J. Jin, J.-W. Lee, H.Y. Kim, S.G. Hwang, M. Cho, K.S. Lee, K.-H. Han, S.H. Ahn
Journal: Journal of Hepatology (2016)
Evaluation of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Non-Hodgkin’s Lymphoma (NHL) Having Previously Received Autologous Stem Cell Transplant (ASCT).
Authors: Samuel A. Jacobs, Barry McCook, Frank Torok, Norbert Avril, Nick Vidnovic, Judy Joyce, Arturo Molina
Journal: Blood (2004)
Transcriptional Response to IL-7 by Immature Human Thymocytes Demonstrates Specific Effects on Differentiation as Well as Survival Maintenance and Proliferation.
Authors: S. Senadheera, A. George, L. Barsky, E. Zielinska, E. Dudl, B. Schaub, T. Triche, P. Marjoram, K. Weinberg
Journal: Blood (2004)
MIR135A-Mediated Downregulation of Protein-Tyrosine Phosphatase Delta is a Candidate Driver of HCV-Associated Hepatocarcinogenesis
Authors: N. Van Renne, F.H.T. Duong, C. Gondeau, D. Calabrese, N. Fontaine, A.A. Roca-Suarez, P. Pessaux, M.H. Heim, T.F. Baumert, J. Lupberger
Journal: Journal of Hepatology (2016)
BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling
Authors: Guillaume Andrieu, Anna H. Tran, Katherine J. Strissel, Gerald V. Denis
Journal: Cancer Research (2016)

The bromodomain and extraterminal (BET) proteins are epigenetic "readers" of acetylated histones in chromatin and have been identified as promising therapeutic targets in diverse cancers. However, it remains unclear how individual family members participate in cancer progression and small molecule inhibitors such as JQ1 can target functionally independent BET proteins. Here, we report a signaling pathway involving BRD4 and the ligand/receptor pair Jagged1/Notch1 that sustains triple-negative breast cancer migration and invasion. BRD4, but not BRD2 or BRD3, regulated Jagged1 expression and Notch1 signaling. BRD4-selective knockdown suppressed Notch1 activity and impeded breast cancer migration and invasion. BRD4 was required for IL6-stimulated, Notch1-induced migration and invasion, coupling microenvironment inflammation with cancer propagation. Moreover, in patients, BRD4 and Jagged1 expression positively correlated with the presence of distant metastases. These results identify a BRD4/Jagged1/Notch1 signaling pathway that is critical for dissemination of triple-negative breast cancer. Cancer Res; 76(22); 6555-67. ©2016 AACR.
Osteopontin Promotes Cholangiocyte Chemokine Secretion and Macrophage Accumulation in Murine Liver Fibrosis
Authors: J.D. Coombes, P.P. Manka, M. Swiderska-Syn, D. Reid, A. Riva, L.C. Claridge, L. Dolle, R. Younis, M.A. Briones-Orta, N. Kitamura, K. Mehta, Z. Mi, P.C. Kuo, R. Williams, A.M. Diehl, L.A. van Grunsven, S. Chokshi, B. Eksteen, A. Canbay, W.-K. Syn
Journal: Journal of Hepatology (2016)
Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: A subgroup analysis of the JACCRO CC-05/06.
Authors: Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
Journal: Journal of Clinical Oncology (2016)

613 Background: Sub-analyses of US and European randomized trials have demonstrated that primary tumor location is a critical prognostic factor in mCRC treated with 1st-line chemotherapy; moreover, left-sided tumor location may be a predictor of cetuximab efficacy in KRAS exon 2 wild-type tumors (Loupakis F, et al. J Natl Cancer Inst 2015; von Einem JC, et al. J Cancer Res Clin Oncol 2014). We therefore investigated the prognostic impact of primary tumor location on outcomes of Japanese pts enrolled in JACCRO CC-05 or CC-06 trial, which evaluated efficacy of cetuximab in combination with FOLFOX or SOX, respectively, for mCRC with KRAS exon 2 wild-type tumors. Methods: This study evaluated the association of tumor location with overall survival (OS) and progression-free survival (PFS) in mCRC pts from 2 phase II trials of 1st-line therapy; JACCRO CC-05 of cetuximab plus FOLFOX (n= 57, UMIN000004197) and CC-06 of cetuximab plus SOX (n= 67, UMIN000007022). Tumors proximal or from left flexure to rectum were defined as right-sided or left-sided, respectively. Results: In total of 124 pts of the 2 trials, 110 pts were assessable for the primary tumor location: 90 pts with left-sided tumors and 20 pts with right-sided tumors. In the population consists of 110 evaluable pts, median PFS was 9.4 months, and median OS was 33.9 months. Left-sided tumors were significantly associated with longer OS (36.2 months vs. 12.6 months, HR 0.28, 95%CI 0.15-0.53, p&lt; 0.0001) and PFS (11.1 months vs. 5.6 months, HR 0.47, 95%CI 0.29-0.82, p= 0.0041) compared to right-sided tumors. The association was evident in the group of FOLFOX (p&lt; 0.0001 for OS and p= 0.0002 for PFS), while there was a trend in OS of the group of SOX (p= 0.079). In the FOLFOX-group, median OS and PFS were 5.7 and 3.0 months, respectively, for right-sided tumors (n= 9) and 42.8 and 11.3 months, respectively, for left-sided tumors (n= 43). Conclusions: Our study demonstrates that primary tumor location may serve as a predictor of prognosis of mCRC pts treated with cetuximab plus oxaliplatin-based therapy, potentially confirming the prognostic impact of tumor location.
IL-4/IL13 Signaling Acts through M2 Macrophages, but not Th2 T Cells or Hepatocytes to Drive Progression of CCL4-Induce Liver Fibrosis
Authors: S.Y. Weng, X. Wang, S. Vijayan, Y.O. Kim, L. Kaps, Y. Tang, J. Crosby, M. McCaleb, F. Brombacher, A. Waisman, D. Schuppan
Journal: Journal of Hepatology (2016)
Risk Factors of Candidemia in Cirrhotic Patient Hospitalized in a Non Transplant Hepatology-Oriented Intensive Care Unit
Authors: C. Zylberfajn, A. Hoogvorst, A. Checinski, S. Charpentier, P. Cruaud, M. Lescat, P. Nahon, R. Amathieu
Journal: Journal of Hepatology (2016)
Efficacy of Daclatasvir/Asunaprevir for Patients with Chronic Hepatitis C 1B Complicated with Renal Insufficiency
Authors: M. Atsukawa, N. Shimada, A. Tsubota, H. Abe, T. Okubo, A. Nakagawa, T. Arai, N. Itokawa, C. Kondo, Y. Tanaka, Y. Aizawa, K. Iwakiri
Journal: Journal of Hepatology (2016)
SOF/VEL for 12 Weeks Results in High SVR12 Rates in Subjects with Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy from the Astral-1, Astral-2 and Astral-3 Studies
Authors: K. Agarwal, K. Patel, D. Samuel, M. Bourliere, Z. Younes, T. Morgan, S. Strasser, B. Leggett, L. Liu, X. Ding, J. McNally, A. Osinusi, D. Brainard, M. Subramanian, N. Afdhal
Journal: Journal of Hepatology (2016)
GENE EXPRESSION SIGNATURE IS A POTENTIAL PREDICTIVE FACTOR FOR EFFICACY OF MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC)
Authors: J Jassem, Johan Vansteenkiste, M Zielinski, J Dahabreh, A Linder, F Lehmann, B Dizier, P Therasse, J Louahed, V. G Brichard
Journal: Annals of Oncology (2008)
Efficacy of Treatment Using Direct Acting Antiviral Drugs (DAAS) in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma – Real Life Data
Authors: O. Waidmann, M.-W. Welker, N. Weiler, S. Zeuzem, C. Sarrazin, J. Vermehren
Journal: Journal of Hepatology (2016)
Effect of IFN therapy and amino acid substitutions in the hepatitis C virus (HCV) core region on hepatocarcinogenesis in HCV-related cirrhotic patients.
Authors: M. Hirakawa, K. Ikeda, N. Akuta, Y. Kawamura, T. Hosaka, M. Kobayashi, F. Suzuki, Y. Suzuki, Y. Arase, H. Kumada
Journal: Journal of Clinical Oncology (2010)

4009 Background: Although some reports have shown that interferon (IFN) can reduce the hepatocarcinogenesis in HCV-related noncirrhotic and cirrhotic patients through reduction or complete remission of inflammatory activity, the effect of IFN therapy without anti-inflammation has not been clear. In patients with HCV genotype 1b(HCV-1b), amino acid (aa) substitutions in hepatitis C virus core region (HCVCR) are negative predictors of virologic response to pegylated interferon plus ribavirin and they may be one of the important predictors of hepatocarcinogenesis. Then, the purpose of this study is to evaluate the effect of IFN therapy and aa substitutions in HCVCR on the carcinogenesis in HCV-related cirrhotic patients. Methods: The hepatocellular carcinogenesis rate was analyzed statistically in 1,015 patients with cirrhosis C: 268 with IFN therapy and 747 without IFN therapy. HCV genotyping was performed in 818 patients. As for HCV-1b, aa substitution was measured using the PCR Method with mutation-specific primer as an alternative to the direct sequencing method. Results: Hepatocarcinogenesis rates in sustained virological responder (SVR), biochemical responder (BR), non responder (NR) and untreated groups were 29%, 38%, 54% and 57% at the end of the tenth year. The carcinogenesis rate in SVR/BR is lower than that in untreated group. As for male patients with Child-Pugh A, the carcinogenesis rate in NR group is lower than that in untreated group (p = 0.058). The carcinogenesis rate in NR patients who received IFN therapy for 3 years or longer was lower than that in NR patients who received shorter IFN therapy (p = 0.030). Multivariate analysis showed that the risk of carcinogenesis was decreased to 0.52 (p = 0.003) and 0.53 (p = 0.012) in SVR/BR and in NR with 3 years or longer IFN therapy, respectively. In patients with HCV-1b, the hazard ratio of non-double wild aa in core region was 2.01 (p < 0.0001). Conclusions: IFN therapy should be continued in HCV-related cirrhotic patients as long as possible, because IFN therapy of 3 years or longer can suppress the hepatocarcinogenesis even when either HCV RNA clearance or ALT normalization cannot be observed. No significant financial relationships to disclose.
Racial disparity and breast cancer in an inner-city academic institution.
Authors: N. Latif, F. N. Rana
Journal: Journal of Clinical Oncology (2010)

e12046 Background: Breast cancer is the most common diagnosed malignancy and second leading cause of cancer related death among American women today. The overall lifetime risk of developing breast cancer is 10% for African American women and 14% for Caucasian women. Despite the lower incidence of breast cancer among African American women they are more likely die from the disease each year compared to Caucasian women. In this retrospective review, we tried to investigate possible reasons for poor out come of breast cancer in African American patients in our institution. Methods: This is a retrospective review of the tumor registry data from electronic medical records of patients diagnosed with breast cancer at University of Florida Shands Jacksonville from 2000 to 2005. Results: Advanced stage breast cancer was present in 43% of African American women (95% confidence intervals [CI] 35% to 49%) and in 28% of Caucasian females (95% CI 22% to 33%), and this was statistically significant (p = 0.0007). Aggressive breast cancer (triple negative) was present in 12% of African American (95% CI 83% to 93%) and 7% of Caucasian patients (95% CI 90% to 96%) although it was not statically significant but trending more towards African American women (p = 0.074). ER/PR was positive in 60% (95% CI 33% to 47%) of African American women and 72% (95% CI 22% to 33%) of Caucasian patients and it was statically significant (p = 0.006). HER2neu was over expressed in 30% (95% CI 61% to 78%) of African American women and 21% (95% CI 72% to 85%) of Caucasian females, and again this was not statistically significant but trending towards African American patients (p = 0.075). At the time of diagnosis 30% of Caucasian and 31% of African American females were premenopausal and this was not significant. There were 54% of Caucasian females had Medicare or private insurance whereas only 32% of African American females had either Medicare or private insurance. The rest of the patients had either charity or no insurance. Conclusions: In our patient population African American female presented with more advanced, aggressive histology, less likely to have hormone receptor positive disease and more were uninsured. No significant financial relationships to disclose.
Human Liver CD8+ T Cells Have a Tissue Resident Phenotype which is Altered in the Presence of Chronic Viral Infection
Authors: F. Stelma, A. de Niet, M.J. Sinnige, K.A. van Dort, E.M.M. van Leeuwen, N.A. Kootstra, H.W. Reesink
Journal: Journal of Hepatology (2016)